ABSTRACT Background/aims To evaluate the vitreous signals obtained on spectral domain optical coherence tomography (SD-OCT) in patients with uveitic cystoid macular oedema (CMO) and compare these signals before and after sub-Tenon's triamcinolone acetonide injection. Methods Retrospective study with standardised longitudinal imaging preintervention and postintervention. The study cohort comprises 22 patients (22 eyes) with uveitic CMO receiving a sub-Tenon's triamcinolone acetonide (STTA) injection. Post hoc analysis of SD-OCT images using custom software provided an 'absolute' measurement of vitreous signal intensity, which was expressed as a ratio to the retinal pigment epithelium intensity ('VIT/RPE-relative intensity') in arbitrary units. Main outcome measure Difference in VIT/RPErelative intensity before and after treatment.
INTRODUCTION
Uveitis, a group of conditions characterised by intraocular inflammation, is a major cause of blindness worldwide. 1 The most common cause of sight loss in uveitis is cystoid macular oedema (CMO), which accounts for around a third of blindness caused by the disease. 2 CMO may be reversible with prompt corticosteroid treatment 3 such as with sub-Tenon's triamcinolone acetonide (STTA), leading to visual recovery. [4] [5] [6] Vitreous inflammation can be seen on examination as a characteristic 'haze', caused by the presence of proteinaceous exudate in the vitreous. The level of vitreous haze is considered to be a good marker of inflammation in the underlying uveal tract. For this reason the National Eye Institute (NEI) 'Vitreous Haze Score' is the trial endpoint most commonly accepted by regulatory bodies. The NEI scale is determined by examining the vitreous using an indirect ophthalmoscope with comparison to standardised photographs. Weaknesses are that it is subjective, non-continuous, poorly discriminatory at lower levels of inflammation and has low sensitivity in a clinical trial context. [7] [8] [9] [10] Optical coherence tomography (OCT), an imaging modality that provides high resolution, cross-sectional images of ocular tissues noninvasively is well established in the measurement of macular pathology, including macular oedema. [11] [12] [13] Most analysis of OCT images is qualitative, but quantitative analysis-such as the measurement of central macular thickness in macular oedema-provides an objective and sensitive measure of deviation from normal, change over time and response to therapy. We and others are using these principles to develop measures all the key components of intraocular inflammation, such that the clinical assessment of uveitis may become more objective and reliable. 8 14-18 We have shown in two independent cohorts using two different OCT platforms that measurements of vitreous inflammation derived from OCT scans are repeatable, reliable and correlated with clinical measures of disease activity, notably the NEI Vitreous Haze Score. 17 18 To help ensure internal standardisation, we used the reflective intensity of the retinal pigment epithelium (RPE) as a reference, thereby producing a ratio ('VIT/RPE-Relative Intensity'). 17 18 The aim of this paper is to further validate the use of the VIT/RPE-relative intensity as a marker of disease activity in uveitis by assessing whether it is capable of detecting changes in the vitreous pre-STTA/post-STTA, and whether these correlate with other signs of reduction in disease activity.
MATERIALS AND METHODS Study population
This is a retrospective, longitudinal study comprising 22 patients with uveitic CMO consecutively attending a tertiary uveitis clinic at the Birmingham and Midland Eye Centre, Sandwell and West Birmingham Hospitals NHS Trust, UK. All patients had a complete ophthalmic assessment including visual acuity, slit lamp examination, grading of anterior chamber inflammation, intraocular pressure measurement, fundus examination and grading of vitreous inflammation using the NEI Vitreous Haze Score. Approval for data collection and analysis was obtained from a UK National Health Service research ethics committee and adhered to the tenets set forth in the Declaration of Helsinki. All patients were consented for posterior STTA administration.
Procedure
Povidone iodine and oxybuprocaine drops were used to sterilise and anesthetise the eye before the procedure. The conjunctiva and sub-Tenon's layer were lifted 10 mm from the limbus superotemporally using blunt serrated forceps. The sub-Tenon's cannula was attached to a 2 mL syringe containing 1 mL of 40 mg/mL triamcinolone acetonide, and inserted, advancing the needle 12-14 mm into the posterior sub-Tenon's space into which the full dose (ie, 40 mg triamcinolone acetonide) was administered. 19 
Image acquisition
Optical coherence tomographic image sets were obtained using Heidelberg Spectralis OCT (Heidelberg Engineering, Germany). The images were obtained immediately prior to the procedure and at the first subsequent clinical review with variable duration to follow-up. The volume scan images were centred on the fovea covering an area of 20°by 20°, and containing a minimum of 25 OCT B-scans. The TruTrack Active and AutoRescan features were used to ensure that follow-up scans were matched to the baseline scan. The enhanced depth protocol was not used.
Quantitative assessment of vitreous signal intensity
As per our previously published protocol, OCT scan images were imported into 'OCTOR', a programme for easy navigation and manual grading of the scans validated in previous studies. 20 21 Masked to all clinical data, primary graders marked out (1) the uppermost extent of the vitreous space included in the scan-the 'vitreous top', (2) the internal limiting membrane, (3) the inner layer of the RPE and (4) the outer layer of the RPE on all the scans. This was done on five sections going through the central fovea subfield of the Early Treatment Diabetic Retinopathy Study grid. The area between lines 1 and 2 was defined as the 'vitreous space' (VIT), while the area between 3 and 4 was defined as the 'RPE space' (RPE). The software then calculated the mean intensity values of all image pixels contained within each space as absolute values. A relative value, the VIT/RPE-relative intensity, could then be derived to minimise the potential effects of confounders such as lens opacities or anterior chamber inflammation (figure 1).
Statistical analyses
Clinical and imaging data were analysed with frequency and descriptive statistics. Snellen visual acuities were converted to LogMAR (logarithm of the minimum angle of resolution) visual acuity for the purposes of statistical analysis. Spearman's correlation was used to assess the relationship between the VIT/ RPE-relative intensity and clinical/retinal imaging parameter. The Mann-Whitney U test was used in independent samples and Wilcoxon signed-ranks test in dependent samples.
Statistical analysis was performed using IBM SPSS software V.20.0 for Windows (SPSS, Chicago, Illinois, USA). p Values <0.05 were considered significant.
RESULTS

Baseline characteristics
The study included 22 eyes of 22 patients, before and after treatment with STTA. Their baseline characteristics are listed in table 1.
VIT/RPE-relative intensity
Treatment with STTA was associated with a significant reduction in OCT-measured VIT/RPE-relative intensity (figure 2). The mean (SD) VIT/RPE-relative intensity pretreatment was 0.139 (0.074) versus 0.053 (0.028) post-treatment ( p=3×10 −5 ).
Mean central retinal thickness
Treatment with STTA was associated with significant reduction in the OCT-measured mean central 1 mm of retinal thickness (CRT). Mean (SD) CRT was 580.5 μm (119.4 μm) pretreatment versus 332.7 μm (95.4 μm) post-treatment ( p=2×10 −8 ); the mean reduction in CRT was 247.7 (95% CI 189.1 to 306.3). The correlation coefficient between VIT/RPE-relative intensity and change in mean CRT was 0.534 (p=0.01; figure 3 ).
Visual acuities
Treatment with STTA was associated with significant improvement in visual acuity ( p=0.0001). The number of patients with a visual acuity greater than 6/12 increased from 1 (4.5%) to 17 (77.3%) with a corresponding reduction in those with 6/12 or worse from 19 (86.4%) to 5 (22.7%) (Fisher exact test, p=0.0001). Grouping visual outcome by timing of follow-up showed that those with follow-up at 4-8 weeks comprised 14 patients with a visual acuity greater than 6/12 and 3 with 6/12 or worse, whereas those with follow-up at later time points (9-19 weeks) comprised three patients with a visual acuity greater than 6/12 and 2 with 6/12 or worse. The correlation coefficient between VIT/RPE-relative intensity and visual acuity was 0.702 ( p=0.0001).
DISCUSSION
This study provides the first 'treatment-response' data to support our proposal that OCT can be used to provide an objective measure of treatment response in uveitis based on changes in the vitreous. It builds on our previous feasibility study in which we demonstrated proof of concept that the VIT/ RPE-relative intensity could provide an objective and quantitative measure of vitreous inflammation. Both the cross-sectional study and a validation study in an independent cohort showed that the VIT/RPE-relative intensity was higher in uveitic eyes with active inflammation than uveitic eyes without active inflammation or healthy controls, and that it correlated with the clinical NEI Vitreous Haze Score. 17 18 We also showed association with other markers of disease activity such as visual acuity, anterior chamber (AC) cells and AC flare. Importantly, the VIT/ RPE-relative intensity was also shown to be a repeatable measure with high intergrader reproducibility. 17 18 In this study, we have demonstrated that the VIT/RPE-relative intensity decreases significantly in response to STTA and that this reduction was associated with improvement in another measurable sign of disease activity, CMO. Critically, this study demonstrates VIT/RPE-relative intensity is sensitive enough to measure changes in the vitreous undetectable using the clinical NEI Vitreous Haze Score. As highlighted by a number of authors, the poor discrimination of the NEI Vitreous Haze Score at lower levels has led most clinical trials in this field to require subjects to have a minimum NEI Vitreous Haze Score of 2+ for inclusion. This has significantly limited enrolment. 7-10 22 In an observational study comparing a photographic-based score to the NEI score, Hornbeak noted that had they used the traditional 'cut-off ' 86% of participants would have been excluded. Although a significant proportion of that cohort were scored as 0 on the NEI Vitreous Haze Score it cannot be argued that all these cases were inactive as both the Hornbeak study and our current study indicate that an appropriately sensitive tool is able to discriminate within this group. 9 Whereas the Hornbeak study was cross-sectional, our longitudinal study is the first to show a tool capable of detecting change in uveitis activity within these lower levels of inflammation, even when both the pretreatment and post-treatment clinical Vitreous Haze Score was 0.
There is an urgent need to develop sensitive objective measures of inflammation in uveitis, for use as endpoints in clinical trials and to inform treatment decisions in routine clinical practice. The US Food and Drug Administration (FDA) advises that a trial endpoint must be 'well-defined and reliable' and recommends that treatment benefit should be a measure of how a patient 'survives, feels or functions'. Other measures that do not capture these are regarded as 'surrogate measures of benefit'.
All measures of disease activity in uveitis are 'surrogate measures'. The FDA requires a surrogate to be 'reasonably likely, based on epidemiologic, therapeutic, pathophysiologic, or other evidence to predict clinical benefit'. In the context of developing and assessing surrogate measures for use as trial endpoints in uveitis, we propose that they must meet two essential criteria:
(1) the surrogate should be 'biologically relevant' given our understanding of the pathophysiology of the disease and (2) the surrogate should be 'functionally relevant' with evidence of a downstream effect on visual function, but recognising that this effect may be delayed and indirect. Provided a surrogate satisfies these criteria, it should then be assessed for desirable criteria such as objectivity, repeatability and sensitivity.
This study provides further evidence of the biological and functional relevance of VIT/RPE-relative intensity. Its biological relevance is demonstrated by its association with other markers of inflammation such as the CRT. Its functional relevance is supported by its correlation with visual recovery, however, it is recognised that this is largely indirect, the primary mechanism of improvement being the restoration of central macular architecture as the oedema resolves.
The OCT-derived VIT/RPE-relative intensity is the first instrument-measured marker of vitreous inflammation, and is an example of how extended applications of OCT and other imaging modalities have the potential to revolutionise our approach to the diagnosis, assessment and management of uveitis. Research into VIT/RPE-relative intensity levels during the development of CMO and its relation to vascular changes visualised on fluorescein angiography may inform our understanding of the natural history of this sight-threatening complication, and help guide treatment. A specific consideration of the use of the Vit/RPE-relative intensity in the presence of macular pathology is whether changes in the macula itself resulting in an altered RPE signal may affect the ratio. For example, it may be noted that the RPE signal may be slightly attenuated in the presence of severe overlying macular oedema. While this might be problematic for diseases with diffuse macular changes, the area of RPE with reduced signal due to overlying uvetic macular oedema appears to be small relative to the total scan, and thus any impact on the VIT/RPE-relative intensity is minor. We also tested this by assessing absolute vitreous intensity scores (ie, removing any potential contribution from changes in RPE signal) and observed that the reduction in vitreous intensity continued to be highly significant (mean of 0.074 pretreatment reducing to 0.036 post-treatment; p=0.0002), confirming that the observed effect can be confidently attributed to the vitreous changes.
Furthermore, the sensitivity of this small study to detect a change at a highly statistically significant level ( p=0.00003), shows how the acceptance of OCT-derived objective indices could transform our approach to effectiveness trials in uveitis. The limitations of our current endpoints in uveitis provide major constraints to effectiveness trials, 7-10 23 which may lead to a trial 'failing' (ie, not meeting its primary endpoint) even in the presence of an effective therapy. This in turn discourages further investment, and leads to an absence of high-quality trial data to inform clinicians, funders and policy makers with regard to many of the therapies being considered for use in uveitis. The high sensitivity and reproducibility of instrument-based measures such as the OCT-derived VIT/RPE-relative intensity can provide endpoints with much higher 'signal:noise' ratio than current clinical measures enabling smaller, faster and cheaper trials. Such endpoints can already be adopted as 'signals' to inform investment decisions in early phase studies, but their adoption in laterphase licensing studies will depend on achieving the further validation required by regulatory bodies such as the FDA.
Study limitations
This study involves retrospective analysis of longitudinal OCT image sets obtained from a small number of patients with uveitis and OCT-confirmed CMO. It, therefore, has the limitations of a retrospective design, and we acknowledge that given the nature of this cohort the focus of the clinical assessments at the time will have been directed towards the CMO, and not on accurate grading of the clinical vitreous haze. We also note that visual acuity data were recorded as Snellen measurements rather than the preferred LogMAR notation and that the posttreatment visit was not at a single fixed time-point (median 7 weeks; range 4-19 weeks).
It should be noted, however, that the primary focus of this paper is on the post hoc analysis of the OCT image sets and their change over time, rather than on the associated clinical changes.
The design of the study was pragmatic in using scans conducted under normal macular scanning conditions. We and others have proposed a number of techniques for optimising the visualisation of vitreous using current spectral domain and emerging technology. 8 10 17 18 Increasing the proportion of the vitreous which is visualised is likely to improve this technique further, enhancing sensitivity and repeatability; it also enables anatomic localisation of foci of inflammation within the vitreous cavity related to the distribution and type of uveitis. In future studies, we also intend to explore the effect of other factors such as rotation of the eye on the vitreous signal.
This study is based on a small cohort, with a range of uveitic diagnoses. This heterogeneity is common in uveitis studies, 8 10 and indeed the consistent performance of the VIT/RPE-relative intensity tool across this range of patients is very encouraging for its future usefulness as an outcome measure. Critically, despite its size and heterogeneity, the study achieved its primary endpoint at a high level of statistical significance.
A barrier to the potential adoption of our technique as described in this study is that it is time-consuming, taking around 3-5 min per scan. Recently, however, we have developed a software package for automation of this process. This custom software entitled VITreous ANalysis (VITAN) can segment and annotate the scans automatically, reducing the time taken to derive measures of vitreous reflectivity to a few seconds per scan, with benefits in speed, cost and further reduction of subjectivity or human error in marking the boundaries of anatomical structures. 24 To conclude, in this study we have further demonstrated the relevance of the OCT-derived VIT/RPE-relative intensity as a quantitative and objective marker of disease activity and treatment response in uveitis complicated by CMO. This first longitudinal study of this novel OCT parameter is an encouraging step in the development of sensitive objective OCT-based endpoints for trials of efficacy in uveitis.
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